Securities Litigation Funding: Financing Fraud and Class Action Claims

How funders evaluate securities fraud claims, class certification risk, and the damages models that drive recovery.

Securities litigation funding finances claims arising from alleged violations of federal securities laws, most commonly under Section 10(b) of the Securities Exchange Act and Rule 10b-5. These cases allege that a company or its officers made material misrepresentations or omissions that distorted the price of securities, causing losses to investors who traded at inflated prices. Because securities class actions involve complex damages analysis, contested class certification, and well-funded corporate defendants, they are capital-intensive and well suited to third-party funding.

The elements of a 10b-5 claim shape the underwriting. A plaintiff must establish a material misrepresentation or omission, scienter, a connection to the purchase or sale of a security, reliance, economic loss, and loss causation. The Private Securities Litigation Reform Act imposes heightened pleading standards that screen out weak cases at the motion to dismiss stage, so a claim that survives dismissal has already cleared a meaningful hurdle. Funders weigh the strength of the alleged misstatements, the evidence of scienter, and the procedural posture when sizing an investment.

Class certification is the pivotal event in most securities cases. Certification under the fraud-on-the-market presumption depends on showing that the security traded in an efficient market, which is typically contested through competing expert testimony on market efficiency and price impact. A certified class dramatically increases the settlement value and the defendant's incentive to resolve, while a denial of certification can reduce the case to a fraction of its expected value. Funders therefore model certification probability as a primary driver of expected recovery.

Damages in securities cases turn on event studies that isolate the portion of a stock's price decline attributable to the alleged fraud, consistent with the loss causation principles articulated in Dura Pharmaceuticals. These analyses are highly expert-dependent and can vary widely, so funders scrutinize the damages methodology and the credibility of the supporting economists. The realistic range of recovery, discounted for certification and liability risk and for the time to resolution, determines whether the investment supports the funder return.

Criterica Capital evaluates securities litigation using outcome models trained on 106M+ court records, including the disposition history of comparable federal securities dockets. This informs our assessment of dismissal risk, certification probability, and settlement timing with greater precision than qualitative judgment alone. Institutional investors and firms pursuing securities claims can contact our team to discuss funding structures.

Discuss your matter with our institutional team.